Louis Garguilo


  • 5/16/2022

    We recently discussed a “mutual growth” strategy for working with smaller to mid-sized CDMOs. Now we’re on to a “bigger-than-you” strategy for biotechs working with “Big CDMO.”

  • 5/9/2022

    There's an opportunity - and strategy - for a biotech to grow as your CDMO partners are growing, says a former Genzyme executive and now industry consultant. And if the CDMO is already big, there's a plan for that as well.

  • 5/2/2022

    Rodney Dangerfield's schtick revolved around his saying, “I don’t get no respect.” In the biopharma industry, process development (PD) may be our Dangerfield. However, giving short shrift to the art, science – and need – of PD can end up leading you down a primrose path.

  • 4/28/2022

    Lightning strikes: Your once early-phase program suddenly arrives at the precipice of commercial approval. Large scale production looms. An experienced CEO warns executives starting out with one outsourcing model must now recognize a future including the bigger “tier” of CDMOs.

  • 4/25/2022

    Outsourcing is a risk-laden operational strategy, but to a lesser degree if you’re an organization with an outsourcing professional like Kent Pryor. CEO or otherwise: Do you or your colleagues fit that bill? The answer could be vital to your chances of success.

  • 4/18/2022

    “We are a biotech that makes money,” replies Helen Torley, CEO, Halozyme, when I ask her what her company is exactly. A significant amount of money, along with notably high margins, and plenty of new drug opportunities. Here's the model for success.

  • 4/11/2022

    Halozyme's API production has occurred at two U.S.-based CDMOs since its first commercial approval in 2013. The biotech works closely with both on new API generations and biologic processes, leading to additional regulatory filings. Here's a key ingredient to that success.

  • 4/4/2022

    In this final look at Chief Technology Officers, all readers will find leadership lessons. CTOs are asking: What do we need to grow into our expanded roles? Top of the agenda: "Connecting as human beings, as innovative and committed leaders, serving all our stakeholders.” 

  • 4/1/2022

    In 1996, “while in grad school at MIT, my professor tossed me into the back of a truck along with the chemicals, and moved to The Scripps Research Institute in San Diego.” So recalls Kent Pryor on how he would wind up a component of the Southern California biotechnology boom, and an outsourcing phenom.

  • 3/29/2022

    An experienced CEO is undertaking a manufacturing risk and opportunity strategy. He's included CDMOs and other external experts in the analysis. That analysis now sits before the board. Key is how much capacity to build, how much to outsource. The main object is to control time.


Louis Garguilo

Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.